ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
The TUBA1B-G3BP2 Axis Sustains p65 Transcriptional Activity to Promote Hepatocellular Carcinoma Progression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, yet mechanisms sustaining malignant progression remain incompletely defined. Integrative analyses across multiple HCC cohorts identified TUBA1B as one of the most consistently upregulated tubulin isotypes whose high expression associates with poor prognosis and metastasis. In hydrodynamic tail-vein injection (HTVi) models, co-expression of Tuba1b with myr-AKT enhanced liver tumor growth, supporting a tumor-promoting role for Tuba1b in vivo. TUBA1B knockdown suppressed HCC cell proliferation, migration, and invasion in vitro and reduced tumor growth and metastasis in orthotopic models. HTVi-mediated delivery of sgTuba1b suppressed hepatocarcinogenesis in NRasV12/myr-AKT- and MYC/sg-p53 HCC models and prolonged survival in the former, whereas sgTuba1b delivery to normal livers caused no detectable histological abnormalities. Mechanistically, TUBA1B bound and stabilized G3BP2 by restraining TRIM25-dependent K48-linked ubiquitination, thereby promoting G3BP2-IκBα association and sustaining basal NF-κB/p65 transcriptional activity; enforced G3BP2 expression rescued the proliferative and metastatic defects caused by TUBA1B loss. Clinically, combined upregulation of TUBA1B and G3BP2 with elevated p65 activity delineated a high-risk HCC subgroup with the poorest outcomes. Collectively, these findings define a TUBA1B-G3BP2 stability axis that supports malignant phenotypes and highlight a potential therapeutic vulnerability in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.